JENTADUETO® has demonstrated significant & sustained efficacy.

Start your metformin-uncontrolled patients with JENTADUETO® for powerful HbA1c reductions:1,2

JENTADUETO® has demonstrated significant and sustained efficacy

Powerful HbA1c reductions at 24 weeks for high baseline metformin-uncontrolled patients (HbA1c ≥ 8.5%)1

TRAJENTA® HbA1c reduction (linagliptin + met 1,000 mg bi-daily)
HbA1c REDUCTION
(linagliptin + met 1,000 mg bi-daily)1
JENTADUETO® Linagliptin + metformin showed sustained efficacy up to 2 years
Linagliptin + metformin showed sustained efficacy UP TO 2 YEARS2